Cargando…
Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory
Autores principales: | Yoon, Jong Pil, Jung, Young Soo, Kim, Dong Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085349/ https://www.ncbi.nlm.nih.gov/pubmed/35571584 http://dx.doi.org/10.1016/j.xrrt.2022.04.005 |
Ejemplares similares
-
Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries
por: Sharun, Khan, et al.
Publicado: (2021) -
Utility of skin testing in assessment of post-AZD1222 vaccine (AstraZeneca) allergic reactions: case series in Vietnam
por: Vu, Mai Thi, et al.
Publicado: (2021) -
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
por: Fragoso, Yara D, et al.
Publicado: (2022) -
Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023) -
A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
por: Villa, Miguel, et al.
Publicado: (2021)